Sara Prickett
Chief Scientific Officer Aravax
Sara Prickett has over 25 years’ research experience in cellular immunology in the fields of Infection and Immunity and then Allergy, including 10 years within Biotech. She is a co-founder and Chief Scientific Officer of Aravax where she has overseen the transitioning of Aravax’s peanut allergy peptide therapeutic from basic research into commercial development, through to Phase 2 trials. Prior to Aravax, Dr Prickett held senior research posts at Alfred Health and Monash University where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax. Dr Prickett received her Bachelor of Science from Sheffield University and PhD from Imperial College, London
Seminars
Wednesday 4th March 2026
Rationally Designed Peptide Immunotherapy for Peanut Allergy: Bringing Antigen-Specific Immune Tolerance into Late-Stage Clinical Reality
10:00 am
- Exploring Aravax’s peptide-based immunotherapy that is designed to induce antigenspecific immune tolerance by precisely targeting T-cells
- Delving into the translational strategy that has led to late phase II clinical trials
NEW DATA
